Gilead Sciences

Among the leading biotech and emerging pharmaceutical companies, Incyte (NASDAQ: INCY) and Pharmacyclics (NASDAQ: PCYC) saw the largest percentage declines in short interest between the January 15 and January 31 settlement dates. Short sellers shied away from Alexion Pharmaceuticals, Amgen, Biogen...

U.S. stocks finished the day almost unchanged as investors and traders were presented with a mixed bag of data today. A better than expected report on the service sector negated another report that showed that companies added fewer employees to their payrolls than anticipated in January. The...

U.S. stocks rose today as investors and traders felt that there were plenty of bargains in the market to be found. "Today is just a bounce. I don't think there is really that much behind it, other than some bargain hunters stepping in," Robert Pavlik, a chief market strategist said to CNBC....

Traders know the markets are in a bad way when construction spending and manufacturing data can spark a 300-point plunge in the Dow. The Dow ended down two percent to close at 15,372.80. The S&P fell 2.3 percent to 1,741.89 and the NASDAQ had the worst day falling 2.6 percent to 3,996.96...

January, with its five percent correction, is behind us, and earnings continue to roll out this week, whether or not the groundhog saw his shadow. Highlights will include quarterly results from General Motors (NYSE: GM), Merck (NYSE: MRK), Philip Morris (NYSE: PM) and Walt Disney (NYSE: DIS),...

Among the leading biotech and emerging pharmaceutical companies, Biogen Idec (NASDAQ: BIIB), BioMarin Pharmaceutical (NASDAQ: BMRN) and Medivation (NASDAQ: MDVN) saw the most significant upswings between the December 31 and January 15 settlement dates. Gilead Sciences, Pharmacyclics and Regeneron...

The number of shares sold short in leading biotech and emerging pharmaceutical companies mostly declined between the December 13 and December 31 settlement dates. BioMarin Pharmaceutical (NASDAQ: BMRN), Celgene (NASDAQ: CELG) and Dendreon (NASDAQ: DNDN) led that trend. Short sellers also shied...

Among leading biotech and emerging pharmaceutical companies, the number of shares sold short in Amgen (NASDAQ: AMGN), Gilead Sciences (NASDAQ: GILD) and Pharmacyclics (NASDAQ: PCYC) grew by the largest percentages between the November 29 and December 13 settlement dates. Medivation saw its short...

After much anticipation and heavily speculation the Federal Reserve announced a $10 billion per month taper. Treasury purchases will be cut to $40 billion per month with MBS purchases cut to $35 billion per month. The Fed's move shouldn't come as a surprise as recent economic data and...

U.S stocks started off the week on a positive note with triple digit point gains for the Dow following one of the worst weeks in recent memory. Tuesday is an important day for the markets as the Fed begins its policy meeting which will last until Wednesday. After weeks of anticipating when (or...

Among leading biotech and emerging pharmaceutical companies, the number of shares sold short in Biogen Idec (NASDAQ: BIIB), Celgene (NASDAQ: CELG) and Pharmacyclics (NASDAQ: PCYC) grew by the largest percentages in late November. Gilead Sciences, Regeneron Pharmaceuticals, Seattle Genetics and...

According to Jim Bullard, the chances of the Fed tapering have increased due to recent labor market data. “There is no widely accepted reason why inflation is running as low as it is in the face of extraordinarily accommodative policy for the Fed,” he added. The St. Louis Fed chief added that...

Among leading biotech and emerging pharmaceutical companies, the number of shares sold short in Alexion Pharmaceuticals (NASDAQ: ALXN), BioMarin Pharmaceutical (NASDAQ: BMRN) and Gilead Sciences (NASDAQ: GILD) grew by the largest percentages in late October. Biogen Idec (NASDAQ: BIIB), Illumina...

Among leading biotech and emerging pharmaceutical companies, short sellers retreated from Biogen Idec (NASDAQ: BIIB) by the largest percentage in early October. Amgen (NASDAQ: AMGN), Illumina (NASDAQ: ILMN), Regeneron Pharmaceuticals (NASDAQ: REGN) and Seattle Genetics (NASDAQ: SGEN) saw short...